A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting...

Area of Science:

• Pharmacovigilance and Drug Safety
• Infectious Diseases and Microbiology
• Clinical Pharmacology

Background:

• Omadacycline is a novel antibiotic for community-acquired bacterial infections.
• Comprehensive real-world safety data for omadacycline is limited.
• Understanding adverse drug reactions (ADRs) is crucial for patient safety.

Purpose of the Study:

• To evaluate the real-world adverse drug reactions (ADRs) associated with omadacycline.
• To analyze post-marketing safety data using the FDA Adverse Event Reporting System (FAERS).
• To identify significant safety signals for omadacycline.

Main Methods:

• Analysis of 4541 omadacycline-related reports from FAERS (Q1 2020 - Q4 2024).
• Disproportionality analysis using Reporting Odds Ratio (ROR), Proportional Reporting Ratio, Bayesian Confidence Propagation Neural Network, and Multi-item Gamma Poisson Shrinker.
• Identification of distinct ADRs and assessment of safety signal strength.

Main Results:

• 577 distinct ADRs were identified among 4541 reports.
• Most frequent ADRs: nausea, vomiting, diarrhea, dyspnea, and rash.
• Strongest safety signals included tooth discoloration (ROR=184.33), tongue discoloration (ROR=159.88), and Mycobacterium avium complex infection (ROR=73.30).

Conclusions:

• Omadacycline is associated with gastrointestinal disturbances, dental and tongue discoloration, and respiratory issues.
• Significant safety signals for hepatic events and mortality were observed, warranting vigilance.
• Ongoing pharmacovigilance integrating real-world evidence is essential for omadacycline safety, particularly in elderly and comorbid patients.